Akari Therapeutics (AKTX) announced that it had achieved positive results from its phase 2 study using its drug Nomacopan (Coversin) to treat patients with bullous pemphigoid ((BP)). This could provide patients with a new treatment option other than current drugs that cause adverse events. The biotech will likely be able to expand the study to include a more severe type of population. Because the drug, Coversin, is able to bind to C5 and LTB4 pathways, the biotech has ongoing trials in other rare diseases. One large program involves using the biologic to target